MX2013006464A - Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. - Google Patents
Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.Info
- Publication number
- MX2013006464A MX2013006464A MX2013006464A MX2013006464A MX2013006464A MX 2013006464 A MX2013006464 A MX 2013006464A MX 2013006464 A MX2013006464 A MX 2013006464A MX 2013006464 A MX2013006464 A MX 2013006464A MX 2013006464 A MX2013006464 A MX 2013006464A
- Authority
- MX
- Mexico
- Prior art keywords
- improving
- multiple sclerosis
- laquinimod
- functional status
- life
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004577 laquinimod Drugs 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000006866 deterioration Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000004112 neuroprotection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención objeto proporciona métodos para reducir o inhibir la progresión del nivel de fatiga en un paciente humano con esclerosis múltiple, para mejorar o inhibir el deterioro del estado funcional de un paciente humano con esclerosis múltiple, y para mejorar o inhibir el deterioro de la salud general de un paciente humano con esclerosis múltiple, que comprende administrar oralmente al paciente humano laquinimod o una sal farmacéuticamente aceptable del mismo. La invención objeto también proporciona un método para proporcionar neuroprotección a un sujeto humano, el método que comprende administrar oralmente al sujeto humano laquinimod o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42074210P | 2010-12-07 | 2010-12-07 | |
| US201161542996P | 2011-10-04 | 2011-10-04 | |
| PCT/US2011/063460 WO2012078591A1 (en) | 2010-12-07 | 2011-12-06 | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013006464A true MX2013006464A (es) | 2013-07-29 |
Family
ID=46162796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013006464A MX2013006464A (es) | 2010-12-07 | 2011-12-06 | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20120142730A1 (es) |
| EP (1) | EP2648732A4 (es) |
| JP (2) | JP2013544887A (es) |
| KR (1) | KR20130124518A (es) |
| CN (1) | CN103260624B (es) |
| AU (2) | AU2011338647A1 (es) |
| BR (1) | BR112013014061A2 (es) |
| CA (1) | CA2820586A1 (es) |
| CL (1) | CL2013001602A1 (es) |
| EA (1) | EA201390827A1 (es) |
| IL (1) | IL250726A0 (es) |
| MX (1) | MX2013006464A (es) |
| NZ (1) | NZ611628A (es) |
| PE (1) | PE20140872A1 (es) |
| PH (1) | PH12013501193A1 (es) |
| SG (2) | SG10201509831XA (es) |
| UA (1) | UA111959C2 (es) |
| WO (1) | WO2012078591A1 (es) |
| ZA (1) | ZA201304237B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1937642E (pt) * | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| PL2234485T3 (pl) | 2007-12-20 | 2014-06-30 | Teva Pharma | Stabilne preparaty lakwinimodu |
| KR20160148050A (ko) * | 2009-07-30 | 2016-12-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 크론병의 치료 |
| US9585878B2 (en) | 2009-08-10 | 2017-03-07 | Teva Pharmaceutical Industries, Ltd. | Treatment of BDNF-related disorders using laquinimod |
| PH12012501740A1 (en) * | 2010-03-03 | 2012-11-12 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| KR20160129093A (ko) * | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| WO2012006538A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| US9284276B2 (en) | 2012-02-16 | 2016-03-15 | Teva Pharmaceutical Industries, Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| AU2013323131A1 (en) * | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| JP2015533163A (ja) * | 2012-10-12 | 2015-11-19 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症における視床損傷を低減するためのラキニモド |
| US8975279B2 (en) | 2012-11-07 | 2015-03-10 | Teva Pharmaceutical Industries, Ltd. | Amine salts of laquinimod |
| CA2900503A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| CA2900977A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
| US20150174118A1 (en) * | 2013-12-20 | 2015-06-25 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod to delay huntington's disease progression |
| HK1225969A1 (zh) * | 2014-01-17 | 2017-09-22 | Teva Pharmaceutical Industries Ltd | 利用低剂量的拉喹莫德治疗克隆氏病 |
| HK1231413A1 (zh) * | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| MX2017004808A (es) * | 2014-10-16 | 2017-07-26 | Novartis Ag | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. |
| US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| CN112770748A (zh) * | 2018-10-09 | 2021-05-07 | 美迪诺亚公司 | 异丁司特和干扰素-β的组合及其使用方法 |
| BR112022001138A2 (pt) * | 2019-07-22 | 2022-03-15 | Actelion Pharmaceuticals Ltd | Métodos de tratamento de esclerose múltipla |
| CN110688373A (zh) * | 2019-09-17 | 2020-01-14 | 杭州绿度信息技术有限公司 | 一种基于逻辑回归的offset方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797109B1 (en) * | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| KR20140091778A (ko) * | 2006-06-12 | 2014-07-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| EP2680010A1 (en) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
| SI2442651T1 (sl) * | 2009-06-19 | 2015-10-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje multiple skleroze z lakvinimodom |
-
2011
- 2011-12-06 SG SG10201509831XA patent/SG10201509831XA/en unknown
- 2011-12-06 UA UAA201308448A patent/UA111959C2/uk unknown
- 2011-12-06 MX MX2013006464A patent/MX2013006464A/es unknown
- 2011-12-06 WO PCT/US2011/063460 patent/WO2012078591A1/en not_active Ceased
- 2011-12-06 EP EP11846599.6A patent/EP2648732A4/en not_active Withdrawn
- 2011-12-06 PE PE2013001357A patent/PE20140872A1/es not_active Application Discontinuation
- 2011-12-06 BR BR112013014061A patent/BR112013014061A2/pt not_active Application Discontinuation
- 2011-12-06 EA EA201390827A patent/EA201390827A1/ru unknown
- 2011-12-06 CN CN201180060414.8A patent/CN103260624B/zh not_active Expired - Fee Related
- 2011-12-06 SG SG2013042403A patent/SG190449A1/en unknown
- 2011-12-06 NZ NZ611628A patent/NZ611628A/en not_active IP Right Cessation
- 2011-12-06 US US13/312,284 patent/US20120142730A1/en not_active Abandoned
- 2011-12-06 JP JP2013543255A patent/JP2013544887A/ja active Pending
- 2011-12-06 PH PH1/2013/501193A patent/PH12013501193A1/en unknown
- 2011-12-06 AU AU2011338647A patent/AU2011338647A1/en not_active Abandoned
- 2011-12-06 CA CA2820586A patent/CA2820586A1/en not_active Abandoned
- 2011-12-06 KR KR1020137017362A patent/KR20130124518A/ko not_active Ceased
-
2013
- 2013-06-05 CL CL2013001602A patent/CL2013001602A1/es unknown
- 2013-06-10 ZA ZA2013/04237A patent/ZA201304237B/en unknown
-
2016
- 2016-12-26 JP JP2016251360A patent/JP2017095476A/ja active Pending
-
2017
- 2017-02-22 IL IL250726A patent/IL250726A0/en unknown
- 2017-03-28 AU AU2017202055A patent/AU2017202055A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201509831XA (en) | 2015-12-30 |
| PH12013501193A1 (en) | 2013-07-15 |
| EP2648732A1 (en) | 2013-10-16 |
| CN103260624A (zh) | 2013-08-21 |
| BR112013014061A2 (pt) | 2016-09-13 |
| CL2013001602A1 (es) | 2013-10-25 |
| PE20140872A1 (es) | 2014-08-09 |
| NZ611628A (en) | 2015-06-26 |
| CA2820586A1 (en) | 2012-06-14 |
| ZA201304237B (en) | 2014-08-27 |
| CN103260624B (zh) | 2015-06-03 |
| EA201390827A1 (ru) | 2013-12-30 |
| KR20130124518A (ko) | 2013-11-14 |
| EP2648732A4 (en) | 2014-04-30 |
| JP2013544887A (ja) | 2013-12-19 |
| US20120142730A1 (en) | 2012-06-07 |
| AU2017202055A1 (en) | 2017-04-20 |
| SG190449A1 (en) | 2013-07-31 |
| WO2012078591A8 (en) | 2012-08-02 |
| IL250726A0 (en) | 2017-04-30 |
| UA111959C2 (uk) | 2016-07-11 |
| WO2012078591A1 (en) | 2012-06-14 |
| JP2017095476A (ja) | 2017-06-01 |
| AU2011338647A8 (en) | 2013-09-05 |
| AU2011338647A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013501193A1 (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
| NZ601167A (en) | Treatment of cardiac conditions | |
| IL217901B (en) | Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases | |
| EA033415B1 (ru) | Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2 | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| UA92584C2 (ru) | Применение мелоксикама для лечения респираторных заболеваний у свиней | |
| SG11201400301XA (en) | An orthopedic chair for treatment and prevention of spinal diseases | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| ZA201403596B (en) | Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease | |
| WO2012023623A3 (ja) | ハンター症候群の治療剤 | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| PH12014500381A1 (en) | Therapeutic methods | |
| PH12013501863A1 (en) | Aclidinium for use in improving the quality of sleep in respiratory patients | |
| WO2014026013A3 (en) | Methods for maintaining or improving health, well-being and/or a physiological function in a subject | |
| WO2012040444A3 (en) | Treatment of patients with incipient alzheimer's disease | |
| CY1119845T1 (el) | Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος | |
| ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
| HK1188950A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| UA68922U (ru) | Способ лечения больных гнойно-септической патологией мягких тканей |